Gemini Therapeutics, Inc. (GMTX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Gemini Therapeutics, Inc. (GMTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gemini Therapeutics, Inc. ever had a stock split?
Gemini Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | NASDAQ (NMS) Exchange | 36870G105 CUSIP |
| US Country | 24 Employees | - Last Dividend | 30 Dec 2022 Last Split | - IPO Date |
Overview
Gemini Therapeutics, Inc. is a pioneering clinical stage precision medicine company focused on the development of novel therapeutic compounds specifically designed to address the underlying genetic causes of age-related macular degeneration (AMD), a leading cause of blindness globally. Founded in 2015 and based in the vibrant scientific community of Cambridge, Massachusetts, Gemini Therapeutics is at the forefront of leveraging genetic insights to create targeted treatments for patients suffering from genetically defined AMD, particularly the atrophic form known as dry AMD. The company's multifaceted approach aims not only at slowing the progression of this debilitating eye disease but also at addressing systemic diseases related to the same genetic pathways.
Products and Services
- GEM103
- GEM307
Gemini Therapeutics’ flagship product, GEM103, represents a significant advancement in the treatment of dry age-related macular degeneration (AMD). As a recombinant form of the human complement factor H protein, GEM103 targets the complement pathway, a critical component of the immune system implicated in the progression of AMD. By restoring the balance within this pathway, GEM103 has the potential to directly address the genetic abnormalities that lead to the condition, offering hope for patients with this currently untreatable form of the disease.
Expanding its portfolio beyond ophthalmology, Gemini Therapeutics is also developing GEM307, a therapeutic designed to treat systemic diseases. Although specifics of GEM307's mechanism of action and target diseases are not detailed, its development underscores the company's commitment to leveraging its precision medicine platform to address a broad range of conditions that share genetic foundations. This strategic diversification intends to capitalize on the underlying genetic research and therapeutic development expertise of Gemini Therapeutics, potentially offering novel treatments for diseases with significant unmet medical needs.
